Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer.

Background: With advanced stereoscopic vision, lack of tremor, and the ability to rotate the instruments surgeons find that robotic systems are ideal laparoscopic tools. Because of its high operating cost, however, robotic surgery should be reserved to procedures in which the technology can be of maximum benefit, usually when precise dissections in confined spaces are required. Because conventional laparoscopic total mesorectal excision is a challenging procedure, we have sought to assess the utility of the DaVinci robotic system in laparoscopic low anterior resections for cancer of the rectum.

Increasing the visibility of patient fatigue.

Objectives: To describe the process used by our cancer center to assess staff knowledge and attitudes about cancer-related fatigue, and to change clinical practice of fatigue assessment and management.

Data Sources: Review articles, research studies, guidelines, and questionnaires.

Conclusions: Change in clinical practice occurs slowly.

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Purpose: Tumor angiogenesis mediated by vascular endothelial growth factor (VEGF) is inhibited by the recombinant humanized (rhu) monoclonal antibody (MAb) rhuMAbVEGF, which has synergy with chemotherapy in animal models. The present study was designed to assess the safety and pharmacokinetics of weekly intravenous (IV) rhuMAbVEGF with one of three standard chemotherapy regimens.

Patients And Methods: Twelve adult patients were enrolled four on each combination.